Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Thank you all for your informative posts. I

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
sokol Member Profile
 
Followed By 20
Posts 940
Boards Moderated 0
Alias Born 08/09/15
160x600 placeholder
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
sokol   Sunday, 10/28/18 12:34:56 AM
Re: None
Post # of 232440 
Thank you all for your informative posts. I have been absent posting here because of personal commitments. I do, however, have one comment to offer about the observation that Missling is ”hiding our light” (for a good reason) as Bio put it in a post today, but first I must say that I am very sad about the tragedy that occurred in Bio’s city.

I am convinced Anavex is purposefully not seeking publicity, and that is a good thing for the following reasons.

It is a waste of time for Anavex to attempt to convince the major pharmaceutical companies and the financial media that AVXL 2-73 may be useful in the treatment of AD. AVXL 2-73 is a radical departure from the mainstream theory of treatment of AD. Anavex is developing drugs that are an insult to the establishment, which has made an enormous mistake of investing countless resources and funds in pursuing the wrong path for a treatment or cure of AD, i.e., by merely removing amyloid plaque.

Virtually no one, besides people on this board, is likely to believe that Anavex may be right and all of the major pharmaceutical companies have been wrong all along? What scientist or scientific committee with any major drug company is going to admit that their companies, based on their recommendations, have spent the last decade and enormous sums of money in pursuing the wrong theory. What management of what company is willing to admit to their investors that their amyloid plaque removal drugs do not work? What would happen if they did?

The major drug companies face the necessity of making presentations about their AD drugs at conferences each year. They have no choice but to appear and present the best case they can at conferences like the AAIC and CTAD. What would happen if they did otherwise? So, what do they do? Dress up their pig, apply the best lipstick available, wine and dine the press and the "experts," overwhelm tiny Anavex at these conferences, and kick the can down the road.

What is best for Anavex to do? I think the answer is it is best for Anavex to follow the path of least resistance. Do not fight an uphill battle in the United States. Be fluid and go elsewhere, and that is what Anavex is doing. Australia and Spain are excellent choices for Anavex Trials. Why should Anavex wear itself down taking on the giant pharmaceutical industry in the United States? Here is a portion of my older post about Anavex trials in Australia and Spain:

"Australia and Spain - Excellent Choices for Anavex Trials.

Spain encourages clinical trials to be conducted in country, and Spain passed new regulations on clinical trials to increase transparency and simplify procedures. See: http://www.barcelonaclinicaltrials.org/en/spain-passes-new-regulations-clinical-trials-increase-transparency-and-simplify-procedures.

It seems that recruitment of patients for clinical trials in Spain with its National Healthcare system is likely to move along more quickly than in many other countries. http://www.farmaindustria.es/web_en/documents/press-releases/2017/03/09/clinical-trials-early-stages-growing-steadily-spain-already-make-51-total/....

The Spanish healthcare system is one of the best in the world.
https://www.expatica.com/new/es/healthcare/general-healthcare/healthcare-system-101467/

Life expectancy in Spain ranks number 3 in the world
http://www.worldlifeexpectancy.com/spain-life-expectancy

Spanish have the highest healthy life expectancy in Europe
https://www.theguardian.com/world/2013/mar/05/spanish-highest-life-expectancy-europe

Australia is an ideal country for Alzheimer’s clinical trials because it offers more support for the trials, including funds for our trials.

It has also launched the world-first dementia network to fast-track treatment and research.

https://www.9news.com.au/national/2018/07/02/20/06/australian-dementia-network-launched-to-track-diagnosis-and-care-of-patients”

We now have three clinical trials in progress, and that is where Anavex needs to spend its time and energy. I think Anavex's strategy is to proceed quietly and not make a big fuss about its CNS science and theories that fly in the face of major drug companies. It is best that it go about letting its clinical trials in Australia and Spain proceed and do the speaking instead of wearing itself down fighting against the odds in the United States drug regulatory environment that is dominated by major pharma. Like water, Anavex is seeking the path of least resistance by conducting its clinical trials elsewhere.

“Water is fluid, soft, and yielding. But water will wear away rock, which is rigid and cannot yield. As a rule, whatever is fluid, soft, and yielding will overcome whatever is rigid and hard. This is another paradox: what is soft is strong.”
? Lao Tzu

Anavex is yielding the home court to the pharmaceutical interest in the United States, which they dominate anyway, to avoid powerful forces that may otherwise delay and defeat Anavex. Going to Australia and Spain and sliding under the radar is the softer and stronger approach.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist